Results 71 to 80 of about 36,503 (286)

Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test

Clinical Pharmacology &Therapeutics, EarlyView.
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson, D. Max Smith, Sony Tuteja, Jai N. Patel, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +4 more
wiley   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors

Pharmacogenomics and Personalized Medicine, 2015
DA Sychev,1,2 NP Denisenko,1,2 ZM Sizova,2 AV Grachev,3 KA Velikolug4 1Russian Medical Academy of Post-Graduate Education, 2I.M. Sechenov First Moscow State Medical University, 3SM-Clinic, 4Out-patient department Number 51 branch 3, Moscow, Russia ...
Sychev DA, Denisenko NP, Sizova ZM, Grachev AV, Velikolug KA   +4 more
doaj  

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [PDF]

, 2015
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety.
Bishop, Jeffrey R., Caudle, Kelly E., Chiulli, Dana L., Gaedigk, Andrea, Graham, Rebecca L., Hicks, J. Kevin, Ji, Yuan, Klein, Teri E., Leckband, Susan G., Leeder, J. Steven, LLerena, Adrián, Müller, Daniel J, Sangkuhl, Katrin, Scott, Stuart A., Skaar, Todd C., Stingl, Julia C.   +15 more
core   +1 more source

Genetic Polymorphism of CYP2C19 in Pakistani Population.

Iranian journal of pharmaceutical research : IJPR, 2019
CYP2C19 polymorphism is associated with pretreatment drug response prediction, metabolism, and disposition. Pakistan consists of a population comprising of various ethnic groups residing in different regions of the country each claiming diverse ethnic origins.
Yusra Latif, Sadia Muhammad Din, Muhammad Usman Tareen, Saima Siddiqi, Sana Riaz, Aneesa Sultan, Fizza Tariq, Atika Mansoor   +7 more
openaire   +3 more sources

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source

Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count? [PDF]

, 2010
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91111/1/phco.30.3.265 ...
Bates, Eric R., Dorsch, Michael P., Momary, Kathryn M.   +2 more
core   +1 more source

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies

Clinical Pharmacology &Therapeutics, EarlyView.
The US Food and Drug Administration 2024 guidance prefers regression analysis over categorical analysis for pharmacokinetic data for studies that assess pharmacokinetics in patients with impaired renal functions. The objective of this study was to compare these two statistical methods for pharmacokinetic data analysis of renal impairment studies ...
Gerald Chun‐To So, Ying Grace Li, Stephen D. Hall, Jenny Chien, Christopher D. Payne, Maria M. Posada, Maria Lucia Buziqui Piruzeli, Yan Jin   +7 more
wiley   +1 more source

Cytochrome P4502C19*3 allelic variant frequency in Iranian healthy Azeri Turkish population [PDF]

Journal of Analytical Research in Clinical Medicine, 2016
Introduction: Cytochrome P4502C19 (CYP2C19) is well-known to be one of the determinants responsible for the pronounced interethnic and individual differences in response and character of clinically important drugs.
Nasim Alsadat Didevar, Gholamreza Niaei, Majid Farshdousti Hagh, Bita Amir Taghavi   +3 more
doaj   +1 more source

Stroke genetics: prospects for personalized medicine. [PDF]

, 2012
Epidemiologic evidence supports a genetic predisposition to stroke. Recent advances, primarily using the genome-wide association study approach, are transforming what we know about the genetics of multifactorial stroke, and are identifying novel stroke ...
A Gschwendtner, A Hassan, A Helgadottir, A Helgadottir, A Joutel, A Viswanathan, AB Singleton, AJ Bowes, AV Shirodkar, B Rohrer, C Bellenguez, CAPRIE Steering Committee, CS Ku, D Sibbing, DF Gudbjartsson, DJ Klionsky, DK Wysowski, DL Bhatt, DR Holmes Jr, DS Budnitz, E Flossmann, G Paré, HC Diener, HS Markus, HS Markus, Hugh S Markus, J Hardy, JA Johnson, JB Olesen, JF Meschia, JL Mega, JN Hirschhorn, JT O'Brien, L Wang, M Dichgans, M Kubo, M Serizawa, MA Ikram, MV Holmes, P Jerrard-Dunne, P Kraft, P Polychronopoulos, PC Ng, RL Sacco, RS Epstein, S Bevan, S Gretarsdottir, S Gretarsdottir, S Lanfranconi, S Olsson, S Seshadri, S Seshadri, SE Nissen, The International Warfarin Pharmacogenetics Consortium, VG Manolopoulos, VL Roger   +55 more
core   +2 more sources